[1] 毛晓青,陈钧辉.拓扑异构酶抑制剂——一种新型的抗肿瘤药物[J].中国生化药物杂志(Chin J Biochem Pharmac),2000,21(1):46-8. [2] 蒙凌华,张永炜,丁健.以DNA拓扑异构酶Ⅱ为靶点的抗癌药物[J].中国新药杂志(Chin J New Drug),2002,11(9):675-83. [3] 徐璐,姚明辉.肿瘤化疗的一些新进展[J].国外医药-合成药、生化药、制剂分册(World Pharmacy),2000,21(4):195-9. [4] Corbett TH, LoRusso P, Demchick L, et al. Preclinical antitumor efficacy of analogs of XK469:sodium-(2 [4-(7-chloro-2-quinoxalinyloxy)phenoxy]propionate [J]. Invest New Drug, 1998, 16(2): 129-39. [5] Gao H, Huang KC, Yamasaki EF. XK469, a selective topoisomerase Ⅱ beta poison [J]. Proc Natl Acad Sci USA, 1999, 96(21): 12168-73. [6] Kessel D, Horwitz JP. Pro-apoptotic interactions between XK469 and the peripheral benzodiazepine receptor[J]. Cancer lett, 2001, 168(2):141-4. [7] Hazeldine ST, Polin L, Kushner J, et al. Design,synthesis,and biological evaluation of analogues of the antitumor agent, 2- (4- [(7-chloro-2-quinoxalinyl)oxy]phenoxy)propionic acid (XK469) [J].Med Chem, 2001, 44(11): 1758-76. [8] Kong M, Barnes EA, Ollendorff V, et al. Cyclin F regulates the nuclear localization ofcyclin B1 through a cyclin-cyclin interacton[J].EMBO J, 2000, 19(6): 1378-88. |